Detalles de la búsqueda
1.
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer.
Eur J Nucl Med Mol Imaging
; 51(6): 1741-1752, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38273003
2.
Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
BJU Int
; 133 Suppl 4: 14-22, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37858931
3.
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
Lancet Oncol
; 24(8): e331-e343, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37541279
4.
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.
Eur J Nucl Med Mol Imaging
; 50(12): 3750-3754, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37428216
5.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Eur J Nucl Med Mol Imaging
; 50(5): 1466-1486, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36604326
6.
[18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study.
Eur J Nucl Med Mol Imaging
; 50(11): 3439-3451, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37341747
7.
The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
BJU Int
; 131(3): 330-338, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36069585
8.
Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
BJU Int
; 132(6): 705-712, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37620288
9.
Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study.
Eur J Nucl Med Mol Imaging
; 49(5): 1731-1742, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34725727
10.
Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
BJU Int
; 129(1): 54-62, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34028165
11.
Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
BJU Int
; 129(6): 768-776, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35166426
12.
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
J Urol
; 205(6): 1655-1662, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33530746
13.
Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
J Urol
; 205(4): 1100-1109, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33207138
14.
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
Eur J Nucl Med Mol Imaging
; 48(2): 469-476, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32617640
15.
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Eur J Nucl Med Mol Imaging
; 48(5): 1626-1638, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33604691
16.
Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study.
Eur J Nucl Med Mol Imaging
; 48(9): 2960-2969, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33547552
17.
Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer.
Eur J Nucl Med Mol Imaging
; 48(2): 340-349, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32737518
18.
Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers.
Eur Radiol
; 31(8): 6001-6012, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33492473
19.
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
BMC Cancer
; 20(1): 764, 2020 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32795284
20.
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
BMC Cancer
; 20(1): 884, 2020 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32928177